Clinical Questions

Where the evidence has converged — synthesized from landmark RCTs and meta-analyses across cardiology.

Create a free account to browse the full evidence matrix, follow individual questions, and get notified as new RCTs change the picture.

Does dipyridamole vs placebo improve Left Ventricular Ejection Fraction in Aortic Valve Stenosis? — 2 studies (30 patients) provide low-certainty evidence against benefit of dipyridamole for Left Ventricular Ejection Fraction in Aortic Valve Stenosis.

Does idarucizumab vs placebo improve outcomes in Disseminated Intravascular Coagulation? — Insufficient evidence (1 studies, 11561146 patients) to determine the effect of idarucizumab on Myocardial Infarction Hospitalization in Disseminated Intravascular Coagulation.

Does andexanet alfa vs placebo improve outcomes in Disseminated Intravascular Coagulation? — Insufficient evidence (1 studies, 11561146 patients) to determine the effect of andexanet alfa on Myocardial Infarction Hospitalization in Disseminated Intravascular Coagulation.

Does rivaroxaban vs apixaban improve outcomes in Venous Thromboembolism? — Insufficient evidence (1 studies, 298609 patients) to determine the effect of rivaroxaban on Cardiac Output in Venous Thromboembolism.

Does anakinra vs placebo improve Myocardial Infarction Hospitalization in Diabetes Mellitus, Non-Insulin-Dependent? — Insufficient evidence (1 studies, 60081 patients) to determine the effect of anakinra on Myocardial Infarction Hospitalization in Diabetes Mellitus, Non-Insulin-Dependent.

Does dexmedetomidine vs placebo improve outcomes in Hypertensive disease? — Insufficient evidence (1 studies, 5769 patients) to determine the effect of dexmedetomidine on Acute Kidney Injury in Hypertensive disease.

Does trastuzumab vs methacycline improve outcomes in cancer therapy-related cardiac dysfunction? — Insufficient evidence (1 studies, 1440 patients) to determine the effect of trastuzumab on Cardiac Output in cancer therapy-related cardiac dysfunction.

Does beta blockers vs placebo improve outcomes in Cardiomyopathy, Hypertrophic? — Insufficient evidence (1 studies, 590 patients) to determine the effect of beta blockers on Myopathy / Rhabdomyolysis in Cardiomyopathy, Hypertrophic.

Does ketamine vs xylazine improve Myocardial Infarction Hospitalization in Heart failure? — Insufficient evidence (1 studies, 502 patients) to determine the effect of ketamine on Myocardial Infarction Hospitalization in Heart failure.

Does guideline-directed medical therapy vs placebo improve Myocardial Infarction Hospitalization in secondary mitral regurgitation? — Insufficient evidence (1 studies, 261 patients) to determine the effect of guideline-directed medical therapy on Myocardial Infarction Hospitalization in secondary mitral regurgitation.

Does liraglutide vs placebo improve Left Ventricular Ejection Fraction in Chronic heart failure? — Insufficient evidence (1 studies, 241 patients) to determine the effect of liraglutide on Left Ventricular Ejection Fraction in Chronic heart failure.

Does opioid vs placebo improve outcomes in Total Hip Replacement? — Insufficient evidence (1 studies, 88 patients) to determine the effect of opioid on Cardiac Output in Total Hip Replacement.

Does mrna-based covid-19 vaccine vs placebo improve C-Reactive Protein in Myocarditis? — Insufficient evidence (1 studies, 16 patients) to determine the effect of mrna-based covid-19 vaccine on C-Reactive Protein in Myocarditis.

Does vitamin k antagonist vs antiplatelet improve outcomes in Thromboembolism? — Insufficient evidence (1 studies, 0 patients) to determine the effect of vitamin k antagonist on Myocardial Infarction Hospitalization in Thromboembolism.

Evidence-backed clinical questions